2021
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine
Garakani A. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. Journal Of Psychiatric Practice 2021, 27: 496-497. PMID: 34768276, DOI: 10.1097/pra.0000000000000593.Commentaries, Editorials and LettersConceptsTreatment-resistant depressionElectroconvulsive therapyLiver transplantationChronic treatment-resistant depressionUse of ECTMaintenance electroconvulsive therapyMajor depressive episodeBitemporal treatmentsIntranasal formsIntranasal ketaminePartial responsePrescribed antipsychoticsAdjunctive treatmentAntirejection medicationsChronic migraineMigraine medicationsECT treatmentComorbid migraineDepressive episodePsychotic featuresOrgan transplantationKetamine abuseBrain stimulationClinical considerationsPatientsNeurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study
Amanat M, Rezaei N, Roozbeh M, Shojaei M, Tafakhori A, Zoghi A, Darazam IA, Salehi M, Karimialavijeh E, Lima BS, Garakani A, Vaccaro A, Ramezani M. Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurology 2021, 21: 116. PMID: 33726699, PMCID: PMC7960879, DOI: 10.1186/s12883-021-02152-5.Peer-Reviewed Original ResearchConceptsShortness of breathPredictors of severityTaste dysfunctionNeurological manifestationsNeurological symptomsSevere casesCOVID-19Multicenter prospective clinical studyMulti-center prospective studyHyposmia/anosmiaGuillain-Barré syndromeWeeks of dischargeProspective clinical studyCommon neurological symptomsTime of admissionNon-neurological manifestationsCoronavirus disease 2019COVID-19 diseaseCerebrovascular eventsChest tightnessStatus epilepticusEligible casesNeurological findingsProspective studyMild headacheCommentary on 2 Cases of Neuropsychiatric Symptoms Occurring in Association With COVID-19
Garakani A. Commentary on 2 Cases of Neuropsychiatric Symptoms Occurring in Association With COVID-19. Journal Of Psychiatric Practice 2021, 27: 145-146. PMID: 33656822, DOI: 10.1097/pra.0000000000000527.Commentaries, Editorials and LettersMeSH KeywordsAdultCoronavirusCoronavirus InfectionsCOVID-19HumansMaleMiddle AgedPsychotic DisordersSARS-CoV-2ConceptsPositive COVID-19 testCOVID-19 infectionNeuropsychiatric symptomsPsychotic symptomsSuicide attemptsCoronavirus disease 2019 (COVID-19) infectionCOVID-19Recent respiratory illnessDisease 2019 infectionAcute psychotic symptomsHistory of depressionInpatient psychiatric unitMiddle-age menSerious suicide attemptsCOVID-19 testPatient's symptomsNeuropsychiatric sequelaeRespiratory illnessAntipsychotic medicationPatient's psychosisPsychotic episodeMood symptomsNeurological etiologyPsychiatric historyPsychiatric unit
2020
Commentary on “A New Onset of Mania in a 49-Year-Old Man: An Interesting Case of Wilson Disease”
Garakani A. Commentary on “A New Onset of Mania in a 49-Year-Old Man: An Interesting Case of Wilson Disease”. Journal Of Psychiatric Practice 2020, 26: 510-517. PMID: 33275389, DOI: 10.1097/pra.0000000000000507.Commentaries, Editorials and LettersMeSH KeywordsBipolar DisorderHepatolenticular DegenerationHumansMagnetic Resonance ImagingMaleManiaMiddle AgedConceptsPrimary psychiatric disordersYears of ageWilson's diseasePsychiatric disordersNew onsetDiagnostic workupAcute cognitive declineFormal psychiatric historyCommon clinical manifestationsNeurological side effectsFurther diagnostic workupLow serum ceruloplasminMagnetic resonance imagingSecondary maniaAtypical presentationClinical manifestationsHepatic abnormalitiesPsychiatric providersPatient presentationMetabolism disordersBrain abnormalitiesPsychiatric symptomsTreatment considerationsCorrect diagnosisPsychiatric history
2019
Patient Requests for Discharge from Voluntary Psychiatric Hospitalization: a Chart Review
Garakani A, Appel JM, Aloysi AS, Martinez JM, Larkin K, Buono FD. Patient Requests for Discharge from Voluntary Psychiatric Hospitalization: a Chart Review. Psychiatric Quarterly 2019, 90: 849-859. PMID: 31468251, DOI: 10.1007/s11126-019-09671-y.Peer-Reviewed Original ResearchConceptsPsychiatric hospitalizationAdmission dayUrine toxicologyVoluntary Psychiatric HospitalizationSuicidal ideationNew York City hospitalsPositive urine toxicologyPrevious psychiatric hospitalizationInpatient psychiatric admissionStepwise linear regression analysisCalendar year 2007Chart reviewEarly dischargePsychiatric admissionsPatient outcomesInpatient careTobacco useCity HospitalPatient's requestInpatient servicesLinear regression analysisCigarette usePsychiatric inpatientsVoluntary admissionHospitalization
2018
Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine.
Garakani A. Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine. The Primary Care Companion For CNS Disorders 2018, 20 PMID: 30550646, DOI: 10.4088/pcc.18l02316.Peer-Reviewed Case Reports and Technical Notes
2015
Heart rate and respiratory response to doxapram in patients with panic disorder
Martinez JM, Garakani A, Aaronson CJ, Gorman JM. Heart rate and respiratory response to doxapram in patients with panic disorder. Psychiatry Research 2015, 227: 32-38. PMID: 25819170, PMCID: PMC4420657, DOI: 10.1016/j.psychres.2015.03.001.Peer-Reviewed Original ResearchConceptsPD patientsLF/HFPanic disorderHealthy controlsAnticipatory anxietyPD subjectsParasympathetic componentRespiratory responsesLF/HF ratioSensation of dyspneaHeart rate variability indicesHigher sympathetic activityInjection of salinePanic statesSympathetic activityRespiratory abnormalitiesBrain stemRespiratory stimulantHeart rateParasympathetic responsePanic attacksPatientsExaggerated fear responsePanic symptomsHF ratio
2013
Ophthalmologic Screening in 25 Consecutive Geriatric Psychiatric Inpatient Admissions
Billick SB, Garakani A. Ophthalmologic Screening in 25 Consecutive Geriatric Psychiatric Inpatient Admissions. Psychiatric Quarterly 2013, 85: 49-56. PMID: 23963654, DOI: 10.1007/s11126-013-9269-z.Peer-Reviewed Original ResearchConceptsOphthalmologic screeningAge-related macular degenerationGeriatric psychiatric patientsPsychiatric inpatient admissionsRisk of fallsGeneral physical examinationGeriatric psychiatric inpatientsInpatient psychiatric unitAccurate differential diagnosisQuality assurance reviewGeriatric patientsInpatient admissionsPhysical examinationMacular degenerationDifferential diagnosisVisual abnormalitiesChart documentationOphthalmic problemsPsychiatric unitPsychiatric patientsPsychiatric treatmentPatientsRetinal defectsPsychiatric inpatientsVisual problems
2012
Clinician-rated versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance misuse.
Goldberg JF, Garakani A, Ackerman SH. Clinician-rated versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance misuse. The Journal Of Clinical Psychiatry 2012, 73: 1525-30. PMID: 23290325, DOI: 10.4088/jcp.12m07926.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismBipolar DisorderCross-Sectional StudiesDiagnosis, Dual (Psychiatry)Diagnostic Self EvaluationFemaleHospitalizationHumansInterview, PsychologicalMaleMass ScreeningMiddle AgedObserver VariationPsychometricsReproducibility of ResultsSubstance-Related DisordersYoung AdultConceptsMood Disorder QuestionnaireBipolar disorderSubstance misusePredictive valueHigh negative predictive valuePatient-clinician concordanceLow positive predictive valueDSM-IV-TR criteriaMood disorder patientsHigh prevalence ratesCross-sectional assessmentCurrent substance misuseSubstance use disordersNegative predictive valuePositive predictive valueSubstance use symptomsPsychiatrist's reviewClinician interviewsPositive statusMood disordersPrevalence ratesMood symptomsLifetime substanceUse disordersBipolar diagnosisCerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal Of Affective Disorders 2012, 146: 262-265. PMID: 22840611, DOI: 10.1016/j.jad.2012.06.037.Peer-Reviewed Original Research
2011
PROINFLAMMATORY AND “RESILIENCY” PROTEINS IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION
Martinez JM, Garakani A, Yehuda R, Gorman JM. PROINFLAMMATORY AND “RESILIENCY” PROTEINS IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION. Depression And Anxiety 2011, 29: 32-38. PMID: 21898706, DOI: 10.1002/da.20876.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationBrain-Derived Neurotrophic FactorCyclohexanolsDepressive Disorder, MajorFemaleHumansInflammationInflammation MediatorsInterleukin-1Interleukin-6MaleMiddle AgedNeuropeptide YSeverity of Illness IndexTumor Necrosis Factor-alphaUp-RegulationVenlafaxine HydrochlorideConceptsInflammatory cytokinesDepressed patientsHealthy controlsMajor depressionCSF cytokine levelsCSF of patientsCerebrospinal fluid levelsLumbar puncture procedureNormal comparison groupInflammatory hypothesisNPY concentrationsNPY levelsCytokine levelsIL-6Lumbar punctureClinical severityTreatment protocolIL-1CSF samplesPatientsNeuroprotective peptideFluid levelsSuicidal ideationPuncture procedureSmall sample size
2010
Heart Rate and Blood Pressure Changes During Autonomic Nervous System Challenge in Panic Disorder Patients
Martinez JM, Garakani A, Kaufmann H, Aaronson CJ, Gorman JM. Heart Rate and Blood Pressure Changes During Autonomic Nervous System Challenge in Panic Disorder Patients. Psychosomatic Medicine 2010, 72: 442-449. PMID: 20368476, DOI: 10.1097/psy.0b013e3181d972c2.Peer-Reviewed Original ResearchConceptsLower heart rate variabilityMean diastolic blood pressureHigher heart rateHeart rate variabilityDiastolic blood pressureBlood pressureHealthy controlsHeart ratePanic disorder patientsPD patientsLF/HFOrthostatic challengeSympathovagal balanceDisorder patientsHigher mean diastolic blood pressureGreater cardiac riskIllness severity ratingsLess ill patientsSystolic blood pressureBlood pressure changesSeverity of illnessHigher low-frequency componentsAutonomic nervous systemIll patientsCardiac risk
2008
Effect of medication and psychotherapy on heart rate variability in panic disorder
Garakani A, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Effect of medication and psychotherapy on heart rate variability in panic disorder. Depression And Anxiety 2008, 26: 251-258. PMID: 18839407, DOI: 10.1002/da.20533.Peer-Reviewed Original ResearchConceptsHeart rate variabilityHeart rateRate variabilityLower heart rate variabilitySignificant clinical improvementWeeks of treatmentWeeks of CBTEffects of medicationPanic disorder patientsEffect of treatmentClinical improvementCardiac riskPD patientsCardiovascular diseaseTreatment respondersClinical measuresElevated riskDisorder patientsTreatment phasePatientsSymptom reductionPanic disorderHyperventilation challengeStatistical ManualSignificant decreaseA randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetineShort-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist
2003
Electrolyte-Balanced Sports Drink for Polydipsia-Hyponatremia in Schizophrenia
Quitkin FM, Garakani A, Kelly KE. Electrolyte-Balanced Sports Drink for Polydipsia-Hyponatremia in Schizophrenia. American Journal Of Psychiatry 2003, 160: 385-a-386. PMID: 12562594, DOI: 10.1176/appi.ajp.160.2.385-a.Peer-Reviewed Case Reports and Technical Notes